

Sustained clinically meaningful improvements in walking ability with prolonged-release fampridine: results from the placebo-controlled ENHANCE study.

Peer-reviewed author version

Hobart, Jeremy; Ziemssen, T.; FEYS, Peter; Linnebank, M.; Goodman, A.; Farrell, R.; Englishby, V.; McNeill, M.; Chang, I.; Mehta, L. & Elkins, J. (2016) Sustained clinically meaningful improvements in walking ability with prolonged-release fampridine: results from the placebo-controlled ENHANCE study.. In: MULTIPLE SCLEROSIS JOURNAL, 22, p. 833-834 (Art N° 254).

Handle: <http://hdl.handle.net/1942/24028>

**Abstract:** 254

**Type:** LB Oral

**Abstract Category:** Late Breaking News

**Background:** A hallmark of multiple sclerosis (MS) is walking disability, affecting 80% of people and detected early in the disease course. Maintaining and improving mobility are high priorities for people with MS (PwMS). While clinical trials, observational studies, and patient reports demonstrate consistent benefits of prolonged-release fampridine (PR-FAM; dalfampridine-ER in US), doubts remain whether these benefits are clinically meaningful.

**Objectives:** The Phase 3 ENHANCE trial, the largest and longest randomised trial of PR-FAM to date, was a multicentre, randomised, double-blind, placebo-controlled study to evaluate if PR-FAM 10 mg twice daily (BID) provided sustained clinically meaningful benefits vs placebo on patient-reported walking ability and other functional outcome measures.

**Methods:** ENHANCE enrolled PwMS aged 18-70 yrs, with progressive or relapsing MS, and impaired walking (EDSS 4-7). The primary endpoint was proportion of people with a mean improvement in 12-item MS Walking Scale (MSWS-12) score exceeding a predetermined threshold ( $\geq 8$ -points) from Baseline over 24 wks. Secondary endpoints included: Timed Up and Go (TUG) speed, MS Impact Scale physical subscale (MSIS-29 PHYS), static balance (Berg Balance Scale [BBS]), and upper extremity function (ABILHAND questionnaire). Safety was also assessed.

**Results:** 646 PwMS from 11 countries were randomised to PR-FAM 10 mg BID (n=323) or placebo BID (n=323); 633 (n=315 PR-FAM; n=318 placebo) had  $\geq 1$  dose of PR-FAM and  $\geq 1$  post-Baseline efficacy assessment. Baseline characteristics were similar. Significantly more PR-FAM-treated PwMS achieved a clinically meaningful  $\geq 8$  point improvement in the MSWS-12 (43.2%) vs placebo (33.6%) over 24 wks (OR:1.61 [95% CI:1.15,2.26]; $P=.006$ ). Significantly more PR-FAM PwMS also achieved a  $\geq 15\%$  mean improvement from Baseline over 24 wks on TUG speed vs placebo (43.4% vs 34.7%; OR:1.46 [95% CI:1.04,2.07]; $P=.030$ ). A greater mean improvement from Baseline in the MSIS-29 PHYS was observed in PR-FAM vs placebo (least square mean difference: -3.31 [95% CI:-5.13,-1.50]; $P<.001$ ). Treatment effects favouring PR-FAM, though not statistically significant, occurred in other secondary endpoints. No new safety risks were observed.

**Conclusions:** A significantly greater proportion of PwMS treated with PR-FAM vs placebo achieved clinically meaningful benefits on self-reported walking ability, mobility, and balance, sustained over 24 wks. Safety was consistent with the known PR-FAM profile.

**Disclosure:** Jeremy Hobart: Consulting/advisor fees/honoraria/research support from: Acorda, Biogen, Genzyme, Global blood therapeutics, Merck Serono, Novartis, Tigercat, Vanita;

Tjalf Ziemssen: Advisory boards/trial steering committees/data and safety monitoring committees, and scientific talks/project support from Bayer HealthCare, Biogen, Elan, Genzyme, Merck Serono, Novartis, Roche, Sanofi-Aventis, Synthon and Teva;

Peter Feys: Advisory boards for Biogen and Novartis; speaker for Excemed; editorial board member for *Multiple Sclerosis Journal*;

Michael Linnebank: Grants, funding or honoraria from Bayer HealthCare, Biogen, Genzyme, Merck, Novartis, and Teva;

Andrew Goodman: Paid consultant for AbbVie, Acorda, Atara Biotherapeutics, Bayer, Biogen, Novartis, Sanofi-Genzyme, Teva and Dr. Goodman's employer, the University of Rochester, received research support for conducting clinical trials from the following commercial entities: Acorda Therapeutics, Avanir, Biogen, EMD-Serono, Novartis, Ono, Roche, Sanofi Genzyme, Sun Pharma, Teva;

Rachel Farrell: Consulting / advisor and honoraria from Canbex Therapeutics Ltd, Teva, Biogen, GW Pharmaceuticals;

Veronica Englishby: Employee of and holds stock/stock options in Biogen;

Manjit McNeill: Employee of and holds stock/stock options in Biogen;

Ih Chang: Employee of and holds stock/stock options in Biogen;

Jacob Elkins: Employee of and holds stock/stock options in Biogen;

Lahar Mehta: Employee of and holds stock/stock options in Biogen.

**Source of funding:** Biogen.

Biogen provided funding for medical writing support in the development of this abstract. Juliet Bell (Excel Scientific Solutions, Horsham, UK) wrote the first draft of the abstract based on input from authors. Biogen reviewed and provided feedback on the abstract. The authors had full editorial control of the abstract, and provided their final approval of all content.